Cancer treatment-induced bone loss

Area of Science:

• Oncology
• Endocrinology
• Bone Metabolism

Background:

• Cancer treatment-induced bone loss (CTBL) is a common side effect of various anti-tumor therapies.
• CTBL shares similarities with osteoporosis, increasing fracture risk and impacting patient quality of life.

Purpose of the Study:

• To review the current understanding of CTBL, its clinical implications, and management strategies.
• To highlight the efficacy of existing treatments and the unmet need for bone anabolic therapies in cancer patients.

Main Methods:

• Literature review of studies on cancer treatments and bone loss.
• Analysis of clinical trial data for bisphosphonates and denosumab in CTBL management.
• Discussion of the pathophysiology and clinical presentation of CTBL.

Main Results:

• Bisphosphonates and denosumab have demonstrated efficacy in increasing bone mineral density (BMD) and reducing fracture risk in patients with CTBL.
• Lifestyle modifications like calcium and vitamin D supplementation are recommended but have limited supporting evidence.

Conclusions:

• Effective therapies are crucial for maintaining bone health in cancer patients at risk of CTBL.
• There is a current lack of bone anabolic therapies specifically for cancer patients experiencing bone loss.